Recent studies have underscored that cGAS-STING activation is clinically significant in NSCLC, and have revealed an association between the enhanced expression of cGAS, CCL5 and CXCL10 and a good prognosis in NSCLC patients receiving chemotherapy and immunotherapy [74]. The gene discussed is CGAS; the disease is non-small cell lung carcinoma.